{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T23:25:57Z","timestamp":1793229957916,"version":"4.5.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,28]],"date-time":"2025-03-28T00:00:00Z","timestamp":1743120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Doctoral research Foundation of the First Affiliated Hospital of Gannan Medical University","award":["QD095"],"award-info":[{"award-number":["QD095"]}],"id":[{"id":"https:\/\/ror.org\/040gnq226","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-025-06387-5","type":"journal-article","created":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T01:03:33Z","timestamp":1743210213000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Machine learning models for predicting metabolic dysfunction-associated steatotic liver disease prevalence using basic demographic and clinical characteristics"],"prefix":"10.1186","volume":"23","author":[{"given":"Gangfeng","family":"Zhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yipeng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zenghong","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiang","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangjian","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangcai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8969-7371","authenticated-orcid":false,"given":"Yi","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,28]]},"reference":[{"issue":"4","key":"6387_CR1","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology (Baltimore MD). 2023;77(4):1335\u201347.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"4","key":"6387_CR2","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","volume":"10","author":"N Stefan","year":"2022","unstructured":"Stefan N, Cusi K. A global view of the interplay between non-alcoholic fatty liver disease and diabetes. Lancet Diabetes Endocrinol. 2022;10(4):284\u201396.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6387_CR3","doi-asserted-by":"crossref","unstructured":"Devasia AG, Ramasamy A, Leo CH. Current therapeutic landscape for metabolic Dysfunction-Associated steatohepatitis. Int J Mol Sci. 2025;26(4).","DOI":"10.3390\/ijms26041778"},{"key":"6387_CR4","doi-asserted-by":"crossref","first-page":"101581","DOI":"10.1016\/j.molmet.2022.101581","volume":"65","author":"MY Hochreuter","year":"2022","unstructured":"Hochreuter MY, Dall M, Treebak JT, Barr\u00e8s R. MicroRNAs in non-alcoholic fatty liver disease: progress and perspectives. Mol Metabolism. 2022;65:101581.","journal-title":"Mol Metabolism"},{"issue":"1","key":"6387_CR5","doi-asserted-by":"crossref","first-page":"2458201","DOI":"10.1080\/07853890.2025.2458201","volume":"57","author":"Y Ling","year":"2025","unstructured":"Ling Y, Yang YX, Chen YC, Wang JH, Feng DG, Xiang SJ, et al. Newly identified single-nucleotide polymorphism associated with the transition from nonalcoholic fatty liver disease to liver fibrosis: results from a nested case-control study in the UK biobank. Ann Med. 2025;57(1):2458201.","journal-title":"Ann Med"},{"issue":"2","key":"6387_CR6","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.jhep.2023.03.038","volume":"79","author":"F Tacke","year":"2023","unstructured":"Tacke F, Puengel T, Loomba R, Friedman SL. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol. 2023;79(2):552\u201366.","journal-title":"J Hepatol"},{"issue":"8","key":"6387_CR7","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/S2468-1253(22)00020-6","volume":"7","author":"KWM Abeysekera","year":"2022","unstructured":"Abeysekera KWM, Macpherson I, Glyn-Owen K, McPherson S, Parker R, Harris R, et al. Community pathways for the early detection and risk stratification of chronic liver disease: a narrative systematic review. Lancet Gastroenterol Hepatol. 2022;7(8):770\u201380.","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"6387_CR8","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1021\/acs.jproteome.4c00204","volume":"23","author":"X Li","year":"2024","unstructured":"Li X, Xiao Y, Chen X, Zhu Y, Du H, Shu J, et al. Machine learning reveals serum glycopatterns as potential biomarkers for the diagnosis of nonalcoholic fatty liver disease (NAFLD). J Proteome Res. 2024;23(6):2253\u201364.","journal-title":"J Proteome Res"},{"key":"6387_CR9","doi-asserted-by":"crossref","unstructured":"Rajewski P, Cie\u015bci\u0144ski J, Rajewski P, Suwa\u0142a S, Rajewska A, Potasz M. Dietary interventions and physical activity as crucial factors in the prevention and treatment of metabolic Dysfunction-Associated steatotic liver disease. Biomedicines. 2025;13(1).","DOI":"10.3390\/biomedicines13010217"},{"issue":"7","key":"6387_CR10","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s10654-022-00868-3","volume":"37","author":"S Yuan","year":"2022","unstructured":"Yuan S, Chen J, Li X, Fan R, Arsenault B, Gill D, et al. Lifestyle and metabolic factors for nonalcoholic fatty liver disease: Mendelian randomization study. Eur J Epidemiol. 2022;37(7):723\u201333.","journal-title":"Eur J Epidemiol"},{"key":"6387_CR11","doi-asserted-by":"crossref","unstructured":"Guagnano MT, D\u2019Ardes D, Ilaria R, Santilli F, Schiavone C, Bucci M et al. Non-Alcoholic fatty liver disease and metabolic syndrome in women: effects of lifestyle modifications. J Clin Med. 2022;11(10).","DOI":"10.3390\/jcm11102759"},{"issue":"28","key":"6387_CR12","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.3748\/wjg.v30.i28.3447","volume":"30","author":"B Qu","year":"2024","unstructured":"Qu B, Li Z. Exploring non-invasive diagnostics for metabolic dysfunction-associated fatty liver disease. World J Gastroenterol. 2024;30(28):3447\u201351.","journal-title":"World J Gastroenterol"},{"issue":"47","key":"6387_CR13","doi-asserted-by":"crossref","first-page":"5086","DOI":"10.3748\/wjg.v30.i47.5086","volume":"30","author":"D Ramoni","year":"2024","unstructured":"Ramoni D, Liberale L, Montecucco F. Inflammatory biomarkers as cost-effective predictive tools in metabolic dysfunction-associated fatty liver disease. World J Gastroenterol. 2024;30(47):5086\u201391.","journal-title":"World J Gastroenterol"},{"issue":"3","key":"6387_CR14","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1053\/j.gastro.2022.06.023","volume":"163","author":"MT Long","year":"2022","unstructured":"Long MT, Noureddin M, Lim JK. AGA clinical practice update: diagnosis and management of nonalcoholic fatty liver disease in lean individuals: expert review. Gastroenterology. 2022;163(3):764\u2013e741.","journal-title":"Gastroenterology"},{"issue":"Suppl","key":"6387_CR15","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.3350\/cmh.2022.0436","volume":"29","author":"JH Yu","year":"2023","unstructured":"Yu JH, Lee HA, Kim SU. Noninvasive imaging biomarkers for liver fibrosis in nonalcoholic fatty liver disease: current and future. Clin Mol Hepatol. 2023;29(Suppl):S136\u201349.","journal-title":"Clin Mol Hepatol"},{"issue":"11","key":"6387_CR16","doi-asserted-by":"crossref","first-page":"686","DOI":"10.47102\/annals-acadmedsg.2022284","volume":"51","author":"BP Choo","year":"2022","unstructured":"Choo BP, Goh GBB, Chia SY, Oh HC, Tan NC, Tan JYL, et al. Non-alcoholic fatty liver disease screening in type 2 diabetes mellitus: A cost-effectiveness and price threshold analysis. Ann Acad Med Singapore. 2022;51(11):686\u201394.","journal-title":"Ann Acad Med Singapore"},{"issue":"1","key":"6387_CR17","doi-asserted-by":"crossref","first-page":"2445780","DOI":"10.1080\/07853890.2024.2445780","volume":"57","author":"D Wang","year":"2025","unstructured":"Wang D, Miao J, Zhang L, Zhang L. Research advances in the diagnosis and treatment of MASLD\/MASH. Ann Med. 2025;57(1):2445780.","journal-title":"Ann Med"},{"issue":"1","key":"6387_CR18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/s41574-021-00584-0","volume":"18","author":"N Tamaki","year":"2022","unstructured":"Tamaki N, Ajmera V, Loomba R. Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. Nat Rev Endocrinol. 2022;18(1):55\u201366.","journal-title":"Nat Rev Endocrinol"},{"key":"6387_CR19","doi-asserted-by":"crossref","first-page":"110450","DOI":"10.1016\/j.ejrad.2022.110450","volume":"154","author":"X Guan","year":"2022","unstructured":"Guan X, Chen YC, Xu HX. New horizon of ultrasound for screening and surveillance of non-alcoholic fatty liver disease spectrum. Eur J Radiol. 2022;154:110450.","journal-title":"Eur J Radiol"},{"issue":"48","key":"6387_CR20","doi-asserted-by":"crossref","first-page":"3545","DOI":"10.1038\/s41388-023-02857-6","volume":"42","author":"A Geaney","year":"2023","unstructured":"Geaney A, O\u2019Reilly P, Maxwell P, James JA, McArt D, Salto-Tellez M. Translation of tissue-based artificial intelligence into clinical practice: from discovery to adoption. Oncogene. 2023;42(48):3545\u201355.","journal-title":"Oncogene"},{"issue":"1","key":"6387_CR21","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1186\/s12859-023-05465-z","volume":"24","author":"K Abnoosian","year":"2023","unstructured":"Abnoosian K, Farnoosh R, Behzadi MH. Prediction of diabetes disease using an ensemble of machine learning multi-classifier models. BMC Bioinformatics. 2023;24(1):337.","journal-title":"BMC Bioinformatics"},{"issue":"1","key":"6387_CR22","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1097\/HEP.0000000000000364","volume":"78","author":"J Lee","year":"2023","unstructured":"Lee J, Westphal M, Vali Y, Boursier J, Petta S, Ostroff R, et al. Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study. Hepatology (Baltimore MD). 2023;78(1):258\u201371.","journal-title":"Hepatology (Baltimore MD)"},{"issue":"2","key":"6387_CR23","doi-asserted-by":"crossref","first-page":"91","DOI":"10.11622\/smedj.2021054","volume":"64","author":"JZ Ting Sim","year":"2023","unstructured":"Ting Sim JZ, Fong QW, Huang W, Tan CH. Machine learning in medicine: what clinicians should know. Singapore Med J. 2023;64(2):91\u20137.","journal-title":"Singapore Med J"},{"key":"6387_CR24","doi-asserted-by":"crossref","unstructured":"Cal\u00e8s P, Canivet CM, Costentin C, Lannes A, Oberti F, Fouchard I et al. A new generation of non-invasive tests of liver fibrosis with improved accuracy in MASLD. J Hepatol. 2024.","DOI":"10.1016\/j.jhep.2024.11.049"},{"key":"6387_CR25","doi-asserted-by":"crossref","first-page":"103986","DOI":"10.1016\/j.jbi.2022.103986","volume":"126","author":"O Ben-Assuli","year":"2022","unstructured":"Ben-Assuli O, Jacobi A, Goldman O, Shenhar-Tsarfaty S, Rogowski O, Zeltser D, et al. Stratifying individuals into non-alcoholic fatty liver disease risk levels using time series machine learning models. J Biomed Inform. 2022;126:103986.","journal-title":"J Biomed Inform"},{"issue":"10","key":"6387_CR26","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1111\/liv.16055","volume":"44","author":"S Schophaus","year":"2024","unstructured":"Schophaus S, Creasy KT, Koop PH, Clusmann J, Jaeger J, Punnuru V, et al. Machine learning uncovers manganese as a key nutrient associated with reduced risk of steatotic liver disease. Liver Int. 2024;44(10):2807\u201321.","journal-title":"Liver Int"},{"key":"6387_CR27","doi-asserted-by":"crossref","first-page":"1449064","DOI":"10.3389\/fendo.2024.1449064","volume":"15","author":"H Chen","year":"2024","unstructured":"Chen H, Zhang J, Chen X, Luo L, Dong W, Wang Y, et al. Development and validation of machine learning models for MASLD: based on multiple potential screening indicators. Front Endocrinol (Lausanne). 2024;15:1449064.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"6387_CR28","doi-asserted-by":"crossref","first-page":"e0299487","DOI":"10.1371\/journal.pone.0299487","volume":"19","author":"M McTeer","year":"2024","unstructured":"McTeer M, Applegate D, Mesenbrink P, Ratziu V, Schattenberg JM, Bugianesi E, et al. Machine learning approaches to enhance diagnosis and staging of patients with MASLD using routinely available clinical information. PLoS ONE. 2024;19(2):e0299487.","journal-title":"PLoS ONE"},{"issue":"8","key":"6387_CR29","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1210\/clinem\/dgae060","volume":"109","author":"K Nabrdalik","year":"2024","unstructured":"Nabrdalik K, Kwiendacz H, Irlik K, Hendel M, Dro\u017cd\u017c K, Wijata AM, et al. Machine learning identifies metabolic Dysfunction-Associated steatotic liver disease in patients with diabetes mellitus. J Clin Endocrinol Metab. 2024;109(8):2029\u201338.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"6387_CR30","doi-asserted-by":"crossref","first-page":"e067203","DOI":"10.1136\/bmjopen-2022-067203","volume":"12","author":"RM Carrillo-Larco","year":"2022","unstructured":"Carrillo-Larco RM, Guzman-Vilca WC, Castillo-Cara M, Alvizuri-G\u00f3mez C, Alqahtani S, Garcia-Larsen V. Phenotypes of non-alcoholic fatty liver disease (NAFLD) and all-cause mortality: unsupervised machine learning analysis of NHANES III. BMJ Open. 2022;12(11):e067203.","journal-title":"BMJ Open"},{"issue":"1","key":"6387_CR31","doi-asserted-by":"crossref","first-page":"4942","DOI":"10.1038\/s41598-023-32129-y","volume":"13","author":"F Razmpour","year":"2023","unstructured":"Razmpour F, Daryabeygi-Khotbehsara R, Soleimani D, Asgharnezhad H, Shamsi A, Bajestani GS, et al. Application of machine learning in predicting non-alcoholic fatty liver disease using anthropometric and body composition indices. Sci Rep. 2023;13(1):4942.","journal-title":"Sci Rep"},{"key":"6387_CR32","doi-asserted-by":"crossref","first-page":"846118","DOI":"10.3389\/fpubh.2022.846118","volume":"10","author":"W Ji","year":"2022","unstructured":"Ji W, Xue M, Zhang Y, Yao H, Wang Y. A machine learning based framework to identify and classify Non-alcoholic fatty liver disease in a Large-Scale population. Front Public Health. 2022;10:846118.","journal-title":"Front Public Health"},{"issue":"4","key":"6387_CR33","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1097\/JS9.0000000000001078","volume":"110","author":"R Hu","year":"2024","unstructured":"Hu R, Wu B, Wang C, Wu Z, Zhang X, Chen X, et al. Assessment of transient elastography in diagnosing MAFLD and the early effects of sleeve gastrectomy on MAFLD among the Chinese population. Int J Surg (London England). 2024;110(4):2044\u201354.","journal-title":"Int J Surg (London England)"},{"issue":"3","key":"6387_CR34","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.jhep.2022.11.010","volume":"78","author":"V Ajmera","year":"2023","unstructured":"Ajmera V, Cepin S, Tesfai K, Hofflich H, Cadman K, Lopez S, et al. A prospective study on the prevalence of NAFLD, advanced fibrosis, cirrhosis and hepatocellular carcinoma in people with type 2 diabetes. J Hepatol. 2023;78(3):471\u20138.","journal-title":"J Hepatol"},{"key":"6387_CR35","doi-asserted-by":"crossref","unstructured":"Younossi ZM, Razavi H, Sherman M, Allen AM, Anstee QM, Cusi K, et al. Addressing the High and Rising Global Burden of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH): From the Growing Prevalence to Payors\u2019 Perspective. Alimentary pharmacology & therapeutics; 2025.","DOI":"10.1111\/apt.70020"},{"key":"6387_CR36","doi-asserted-by":"crossref","first-page":"1499013","DOI":"10.3389\/fmed.2024.1499013","volume":"11","author":"S Dawod","year":"2024","unstructured":"Dawod S, Brown K. Non-invasive testing in metabolic dysfunction-associated steatotic liver disease. Front Med (Lausanne). 2024;11:1499013.","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"6387_CR37","doi-asserted-by":"crossref","first-page":"e233513","DOI":"10.1001\/jamanetworkopen.2023.3513","volume":"6","author":"X Wei","year":"2023","unstructured":"Wei X, Lin B, Huang Y, Yang S, Huang C, Shi L, et al. Effects of Time-Restricted eating on nonalcoholic fatty liver disease: the TREATY-FLD randomized clinical trial. JAMA Netw Open. 2023;6(3):e233513.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"6387_CR38","doi-asserted-by":"crossref","first-page":"6212","DOI":"10.1038\/s41598-024-51470-4","volume":"14","author":"Y Xue","year":"2024","unstructured":"Xue Y, Peng Y, Zhang L, Ba Y, Jin G, Liu G. Effect of different exercise modalities on nonalcoholic fatty liver disease: a systematic review and network meta-analysis. Sci Rep. 2024;14(1):6212.","journal-title":"Sci Rep"},{"issue":"1","key":"6387_CR39","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/s41572-025-00599-1","volume":"11","author":"DQ Huang","year":"2025","unstructured":"Huang DQ, Wong VWS, Rinella ME, Boursier J, Lazarus JV, Yki-J\u00e4rvinen H, et al. Metabolic dysfunction-associated steatotic liver disease in adults. Nat Reviews Disease Primers. 2025;11(1):14.","journal-title":"Nat Reviews Disease Primers"},{"issue":"5","key":"6387_CR40","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1053\/j.gastro.2021.07.049","volume":"161","author":"F Kanwal","year":"2021","unstructured":"Kanwal F, Shubrook JH, Adams LA, Pfotenhauer K, Wai-Sun Wong V, Wright E, et al. Clinical care pathway for the risk stratification and management of patients with nonalcoholic fatty liver disease. Gastroenterology. 2021;161(5):1657\u201369.","journal-title":"Gastroenterology"},{"issue":"2","key":"6387_CR41","doi-asserted-by":"crossref","first-page":"C630","DOI":"10.1152\/ajpcell.00123.2022","volume":"323","author":"KQ Deng","year":"2022","unstructured":"Deng KQ, Huang X, Lei F, Zhang XJ, Zhang P, She ZG, et al. Role of hepatic lipid species in the progression of nonalcoholic fatty liver disease. Am J Physiol Cell Physiol. 2022;323(2):C630\u20139.","journal-title":"Am J Physiol Cell Physiol"},{"issue":"4","key":"6387_CR42","first-page":"1080","volume":"165","author":"JJ Wattacheril","year":"2023","unstructured":"Wattacheril JJ, Abdelmalek MF, Lim JK, Sanyal AJ. AGA clinical practice update on the role of noninvasive biomarkers in the evaluation and management of nonalcoholic fatty liver disease. Expert Rev Gastroenterol. 2023;165(4):1080\u20138.","journal-title":"Expert Rev Gastroenterol"},{"key":"6387_CR43","doi-asserted-by":"crossref","unstructured":"Boullion J, Husein A, Agrawal A, Xing D, Hossain MI, Bhuiyan MS et al. Machine Learning-Based biomarker identification for early diagnosis of metabolic Dysfunction-Associated steatotic liver disease. J Clin Endocrinol Metab. 2025.","DOI":"10.1210\/clinem\/dgaf111"},{"key":"6387_CR44","doi-asserted-by":"crossref","first-page":"156082","DOI":"10.1016\/j.metabol.2024.156082","volume":"163","author":"K Stefanakis","year":"2025","unstructured":"Stefanakis K, Mingrone G, George J, Mantzoros CS. Accurate non-invasive detection of MASH with fibrosis F2-F3 using a lightweight machine learning model with minimal clinical and metabolomic variables. Metab Clin Exp. 2025;163:156082.","journal-title":"Metab Clin Exp"},{"key":"6387_CR45","doi-asserted-by":"crossref","first-page":"105837","DOI":"10.1016\/j.ijmedinf.2025.105837","volume":"197","author":"B Ginter-Matuszewska","year":"2025","unstructured":"Ginter-Matuszewska B, Adamek A, Majchrzak M, Rozplochowski B, Zientarska A, Kowala-Piaskowska A, et al. FibrAIm - The machine learning approach to identify the early stage of liver fibrosis and steatosis. Int J Med Informatics. 2025;197:105837.","journal-title":"Int J Med Informatics"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-025-06387-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-025-06387-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,29]],"date-time":"2025-03-29T01:05:00Z","timestamp":1743210300000},"score":1,"resource":{"primary":{"URL":"https:\/\/translational-medicine.biomedcentral.com\/articles\/10.1186\/s12967-025-06387-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,28]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6387"],"URL":"https:\/\/doi.org\/10.1186\/s12967-025-06387-5","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,28]]},"assertion":[{"value":"7 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Review Board of The First Affiliated Hospital of Gannan Medical University (Ganzhou, China). Written informed consent was obtained from all subjects before the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have declared that no competing interest exists.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"381"}}